Brief: Index Pharmaceuticals Gets Cobitolimod Patent in Europe
Aug 2 (Reuters) - InDex Pharmaceuticals Holding AB
INDEX.ST :
* HAS BEEN GRANTED A NEW PATENT IN EUROPE FOR THE COMMERCIAL
FORMULATION OF COBITOLIMOD
* PATENT WILL PROVIDE AN EXCLUSIVITY PERIOD UNTIL SEPT 2042,
WITH
POSSIBILITY OF UP TO 5 YEARS EXTENSION
Source text for Eikon: ID:nWkr2sZrSN
Further company coverage: INDEX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Flerie AB
See all newsBrief: Flerie Q3 Net Asset Value SEK 3,113 Million
Brief: Flerie Portfolio Co Reports Positive Data From Clinical Proof-Of-Mechanism Study
Brief: Flerie Writes Down Value Of Holding In Empros Pharma
Brief: Nasdaq Approves Biosergen's Delisting Application
Brief: Flerie Approves Merger Plan For Flerie And Biosergen